Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting

MLA

Chiappella, Annalisa, et al. “Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting.” Blood, vol. 136, no. 1, Number 1 Supplement 1, Nov. 2020, pp. 12–13. EBSCOhost, https://doi.org/10.1182/blood-2020-140054.

APA

Chiappella, A., Dodero, A., Guidetti, A., Bagnoli, F., Aragona, V., Barbui, A. M., Bramanti, S., Carrabba, M. G., Sorà, F., Zinzani, P., Monfrini, C., Carniti, C., & Corradini, P. (2020). Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting. Blood, 136(1, Number 1 Supplement 1), 12–13. https://doi.org/10.1182/blood-2020-140054

Chicago

Chiappella, Annalisa, Anna Dodero, Anna Guidetti, Filippo Bagnoli, Vanessa Aragona, Anna Maria Barbui, Stefania Bramanti, et al. 2020. “Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting.” Blood 136 (1, Number 1 Supplement 1): 12–13. doi:10.1182/blood-2020-140054.